Ryzumvi™

Drug - Ryzumvi™ (phentolamine ophthalmic solution) [Viatris, Inc.]

July 2025

Therapeutic Area - Mydriasis treatment

Approval criteria

• Age ≥ 3 years; AND
• Patient is undergoing an ophthalmic exam or other procedure involving pharmacologically-induced mydriasis with an adrenergic agonist (e.g., phenylephrine) or parasympatholytic agent (e.g., tropicamide); AND
• Patient does NOT have hypersensitivity to any component of the product; AND
• Patient does NOT have clinically significant ocular disease; AND
• Patient does NOT have ocular infection or inflammation in either eye; AND
• Patient has NOT had ocular trauma, ocular surgery or non-refractive laser treatment within the 6 months prior to use of Ryzumvi

Quantity limits

• One time dose:  2 vials (0.31 mL each)

Questions

Provider Call Center (844) 575-7887